Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamaño-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T, Ramanathan M.

PLoS One. 2013;8(1):e53996. doi: 10.1371/journal.pone.0053996. Epub 2013 Jan 8.

2.

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study.

Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E, Krasensky J, Vaneckova M, Seidl Z, Dwyer MG, Havrdova E, Ramanathan M.

J Neuroimmunol. 2014 Aug 15;273(1-2):58-64. doi: 10.1016/j.jneuroim.2014.04.012. Epub 2014 Apr 30.

PMID:
24907902
3.

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes.

Weinstock-Guttman B, Horakova D, Zivadinov R, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neuroimmunol. 2013 Oct 15;263(1-2):121-7. doi: 10.1016/j.jneuroim.2013.07.010. Epub 2013 Aug 2.

PMID:
23916695
4.

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.

Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G.

Neurology. 2009 Jul 7;73(1):32-8. doi: 10.1212/WNL.0b013e3181aa29fe. Epub 2009 May 20.

5.

Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.

Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ.

JAMA. 2001 Dec 26;286(24):3083-8.

PMID:
11754673
6.

Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis.

Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M.

J Neuroimmunol. 2009 Apr 30;209(1-2):123-30. doi: 10.1016/j.jneuroim.2009.01.023. Epub 2009 Feb 15.

PMID:
19232441
7.

Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis.

Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, James JA.

Mult Scler. 2013 Jun;19(7):891-5. doi: 10.1177/1352458512469693. Epub 2012 Dec 11.

8.

Multiple sclerosis and Epstein-Barr virus.

Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.

JAMA. 2003 Mar 26;289(12):1533-6. Retraction in: Ascherio A, Rubertone M, Spiegelman D, Levin L, Munger K, Peck C, Lennette E. JAMA. 2005 May 25;293(20):2466.

PMID:
12672770
9.

Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.

Gieß RM, Pfuhl C, Behrens JR, Rasche L, Freitag E, Khalighy N, Otto C, Wuerfel J, Brandt AU, Hofmann J, Eberspächer B, Bellmann-Strobl J, Paul F, Ruprecht K.

PLoS One. 2017 Apr 7;12(4):e0175279. doi: 10.1371/journal.pone.0175279. eCollection 2017.

10.

Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, Njølstad G, Pedersen T, Benth JŠ, Wergeland S, Torkildsen O.

Mult Scler. 2014 Dec;20(14):1833-40. doi: 10.1177/1352458514533843. Epub 2014 May 19.

PMID:
24842958
11.

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91. doi: 10.1136/jnnp-2012-304740. Epub 2013 Apr 17.

PMID:
23595944
12.

Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.

Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A.

JAMA. 2005 May 25;293(20):2496-500.

PMID:
15914750
13.

Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.

Langer-Gould A, Wu J, Lucas R, Smith J, Gonzales E, Amezcua L, Haraszti S, Chen LH, Quach H, James JA, Barcellos LF, Xiang AH.

Neurology. 2017 Sep 26;89(13):1330-1337. doi: 10.1212/WNL.0000000000004412. Epub 2017 Aug 30.

14.

Epstein-Barr virus and disease activity in multiple sclerosis.

Buljevac D, van Doornum GJ, Flach HZ, Groen J, Osterhaus AD, Hop W, van Doorn PA, van der Meché FG, Hintzen RQ.

J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1377-81.

15.

Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.

Strautins K, Tschochner M, James I, Choo L, Dunn DS, Pedrini M, Kermode A, Carroll W, Nolan D.

Mult Scler. 2014 Mar;20(3):286-94. doi: 10.1177/1352458513498829. Epub 2013 Jul 25.

PMID:
23886832
16.

Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M.

Ann Neurol. 2010 Feb;67(2):159-69. doi: 10.1002/ana.21886.

17.

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A.

Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9.

18.

Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis.

Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):620-5. doi: 10.1136/jnnp.2008.154906. Epub 2009 Jan 23.

PMID:
19168469
19.

Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait.

Al-Temaimi R, Alroughani R, Jacob S, Al-Mulla F.

J Neuroimmunol. 2015 Aug 15;285:57-61. doi: 10.1016/j.jneuroim.2015.05.021. Epub 2015 May 21.

PMID:
26198919
20.

Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.

Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.

Brain. 2008 Jul;131(Pt 7):1712-21. doi: 10.1093/brain/awn108. Epub 2008 Jun 11.

PMID:
18550621

Supplemental Content

Support Center